In vitro antitumor activity of N-glycosyl sulfonamides

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 22, 2010, Pages 6469-6471

  Crespo, Rosana ^b   De Bravo, Margarita G ^b   Colinas, Pedro A ^a   Bravo, Rodolfo D ^a  

^a FACULTAD DE CIENCIAS EXACTAS   (Argentina)

^b INSTITUTO DE INVESTIGACIONES BIOQUÍMICAS DE LA PLATA INIBIOLP   (Argentina)

Author keywords

Antitumor; Glycosylsulfamides; Glycosylsulfonamides; In vitro

Indexed keywords

(2,4,6 TRI O ACETYL 3 DEOXY ALPHA DEXTRO ERYTHRO HEX 2 ENOPYRANOSYL ETHANESULFONAMIDE); ANTINEOPLASTIC AGENT; CARBOHYDRATE; SULFONAMIDE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CELL STRAIN HEPG2; DRUG SCREENING; DRUG STRUCTURE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; LIVER CELL CARCINOMA; LUNG ADENOCARCINOMA; PROTON NUCLEAR MAGNETIC RESONANCE; STRUCTURE ACTIVITY RELATION;

ADENOCARCINOMA; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; LUNG NEOPLASMS; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES;

EID: 77958033877     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.09.052     Document Type: Article

References (24)

1. World Health Organization, Programmes and Projects: Media Center: Fact Sheets, February, 2006, http://www.who.int/mediacentre/factsheets/fs297/en/.
2. C.F. Mountain Chest 111 1997 1710
3. J.H. Schiller, D. Harrington, C.P. Belani, C. Langer, A. Sandler, and J. Krook N. Eng. J. Med. 346 2002 92
4. C.J. Chen, M.W. Yu, and Y.F. Liaw J. Gastroenterol. Hepatol. 12 1997 S295
5. B.I. Carr Gastroenterology 127 2004 S218
6. D.C. Farrow, T.L. Vaughan, P.D. Hansten, J.L. Stanford, H.A. Risch, M.D. Gammon, W.H. Chow, R. Dubrow, H. Ahsan, S.T. Mayne, J.B. Schoenberg, A.B. West, H. Rotterdam, J.F. Fraumeni Jr., and W.J. Blot Cancer Epidemiol. Biomarkers Prev. 7 1998 97
7. C.T. Supuran Bioorg. Med. Chem. Lett. 20 2010 3467
8. J.Y. Baek, W. Hur, J.S. Wang, S.H. Bae, and S.K. Yoon World J. Gastroenterol. 28 2007 1175
9. Z. Tong, X. Wu, C.-S. Chen, and J.P. Kehrer Lung Cancer 52 2006 117
10. J. Chen, T. Liu, X. Dong, and Y. Hu Mini-Rev. Med. Chem. 9 2009 1174
11. P.A. Colinas, C.A. Témpera, O.M. Rodríguez, and R.D. Bravo Synthesis 2009 4143 and references cited therein
12. C.H. Wong, Carbohydrate-Based Drug Discovery 2003 Wiley-VCH Weinhemin, Germany
13. M. Monsigny, C. Quétard, S. Bourgerie, D. Delay, C. Pichon, P. Midoux, R. Mayer, and A.C. Roche Biochimie 80 1998 99
14. P.A. Colinas, and R.D. Bravo Carbohydr. Res. 342 2007 2297
15. O.M. Rodríguez, P.A. Colinas, and R.D. Bravo Synlett 2009 1154
16. P.A. Colinas, R.D. Bravo, D. Vullo, A. Scozzafava, and C.T. Supuran Bioorg. Med. Chem. Lett. 17 2007 5086
17. Unfortunately the sulfamide analogue derived from per-O-acetylated 2-hydroxy-d-glucal (3) is not stable and decomposed during MTT assay.
18. 50 values were calculated from curves constructed by plotting cell growth inhibition (%) versus compound concentration.
19. T.J. Mosmann Immunol. Methods 65 1983 55
20. S. Pastorekova, M. Barathova, J. Kopacek, and J. Pastorek Carbonic Anhydrase Inhibitors Targeting Cancer: Therapeutic, Immunologic, and Diagnostic Tools Targeting Isoforms IX and XII C.T. Supuran, J.Y. Winum, Drug Design of Zinc-Enzyme Inhibitors: Functional, Structural, and Disease Applications 2009 Wiley Hoboken (NJ) 193
21. M. Lie, N.M. Mazure, V. Hofman, R.E. Ammadi, C. Ortholan, C. Bonnetaud, K. Havet, N. Venissac, B. Mograbi, J. Mouroux, J. Pouysségur, and P. Hofman Br. J. Cancer 102 2010 1627
22. T. Holotnakova, L. Tylkova, M. Takacova, J. Kopacek, J. Petrik, S. Pastorekova, and J. Pastorek J. Hepatol. 35 2001 643
23. J. Chiche, K. Ilc, J. Laferrire, E. Trottier, F. Dayan, N.M. Mazure, M.C. Brahimi-Horn, and J. Pouysségur Cancer Res. 69 2009 358
24. A similar explanation has been previously proposed for the antitumor activity in vitro of pteridine-sulfonamide conjugates: Marques, S. M.; Enyedy, E. A.; Supuran, C. T.; Krupenko, N. I.; Krupenko, S. A.; Santos, M. A. Bioorg. Med. Chem. 2010, 18, 5081.